Fig. 2.

Inhibition of human monocyte-derived dendritic cell (moDC) differentiation by chemotherapeutic agents. Enriched human monocytes were cultured in the presence of granulocyte–macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4 for 6 days. Chemotherapy agents doxorubicin 0·2 μM, cisplatin 25 μM, irinotecan 125 μM and dexamethasone 1 μM, respectively, were added and were present for the whole dendritic cell (DC) differentiation process. The cells were harvested, stained and analysed by flow cytometry on day 6. Percentages of positive cells (Fig. 2a) and mean fluorescent intensity (MFI) (Fig. 2b) for indicated surface markers were measured for the different groups. Data shown are the means from three donors for each condition. Significant results by comparing the chemotherapy-treated group with the control group are indicated (*P < 0·05; **P < 0·01).